Cargando…
A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)
The use of 5α-reductase inhibitors (5α-RIs) as prostate cancer chemoprevention agents is controversial. Two large randomized trials, the Prostate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial, have both shown a decreased incidence of prostat...
Autores principales: | LACY, JOHN M., KYPRIANOU, NATASHA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156162/ https://www.ncbi.nlm.nih.gov/pubmed/25202340 http://dx.doi.org/10.3892/ol.2014.2388 |
Ejemplares similares
-
Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer
por: Fiandalo, Michael V., et al.
Publicado: (2019) -
The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017) -
A Tale of Two Reductases: Extending the Bacteriochlorophyll Biosynthetic Pathway in E. coli
por: Tikh, Ilya B., et al.
Publicado: (2014) -
Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014) -
Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013)